10.1016/j.cmet.2014.04.007 152
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently gained attention for treating multiple medical conditions, including potential to treat IIH
Ipamorelin's defining tolerability feature is selectivity: in its foundational pharmacology it stimulated growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH, and without the appetite stimulation seen with other growth-hormone-releasing peptides avoiding several of their characteristic side effects
Negative points: 4/54 Energy 0/10 points (15.3kJ) Energy intakes above energy requirements are associated with increased risks of weight gain, overweight, obesity, and consequently risk of diet-related chronic diseases
Evidence has demonstrated that iron deposition occurs in the brains of migraine patients (Domnguez et al., 2019)
The SOUL trial also demonstrated that oral semaglutide reduced the risk of adverse cardiovascular events among patients with T2D, ASCVD, and/or CKD over a mean of 47.5 months of follow-up [15]
